Bloodborne Pathogens Exposure Control Plan
6.0 Bloodborne Pathogen Exposure Control Plan Procedures 6.1 OCCUPATIONAL EXPOSURE DETERMINATION The potential for occupational exposure to bloodborne pathogens has been assessed for all WCM employees; and was made without regard to the use of personal protective equipment, as required by the regulations.
Download Bloodborne Pathogens Exposure Control Plan
Information
Domain:
Source:
Link to this page:
Documents from same domain
Compressed Gas Cylinder Storage and Handling
ehs.weill.cornell.edu• Oxygen cylinders should be kept at a minimum of 20 ft away from flammable gases, liquids, solids, greases and oils. • Combustible waste must be kept a minimum of 10 ft away from compressed gas containers and systems. • As per FDNY fire code regulations, flammable gas indoor storage of 3,500 SCF (99.12 m3) or less must be located not ...
Physical Hazards of Machinery and Equipment
ehs.weill.cornell.edu⎯ Circuit interruption devices on an electric motor, such as circuit breakers or overload protection, must require manual reset to restart the motor. Responsibilities Supervisors must: Ensure that equipment users have been properly trained to operate equipment and machinery in a …
Waste Disposal Procedures - Cornell University
ehs.weill.cornell.eduInspecting and auditing College activities to ensure that waste storage and disposal practices are consistent with these procedures. Administration and management of radiological material reception, storage, handling, and use; and radioactive waste
Security of DEA Controlled Substances - Cornell University
ehs.weill.cornell.edu1. DEA Registrants (permit holders) can purchase controlled substances directly from the DEA by submitting DEA Form 222. A copy of the DEA registration must accompany the requisition. The controlled substances must be shipped to the registrant and …
Related documents
Flame Retardants Fact Sheet
www.niehs.nih.govmaking human exposure to it widespread. It has been found in human tissue, and household dust, as well as other places in the environment, including soil, water, and fish. TBBPA appears to have endocrine-disrupting properties. 10. NTP completed the first-ever two-year cancer study of this flame retardant in both mice and
Environmental Health Risk Assessment—Guidelines for ...
www1.health.gov.auEnvironmental Health Risk Assessment—Guidelines for ... ... 1
US EPA - Chemicals Evaluated for Carcinogenic Potential ...
npic.orst.eduThe following list provides an overview of pesticide chemicals evaluated ... The evidence for the human cancer potential and the extent to which a person might be exposed (how much time and to ... 1,3-Dibromo-5,5-dimethylhydantoin 77-48-5 006317 Not Likely to Be Carcinogenic To Humans. 8/28/2000
How States Serve Infants and Their Families Affected by ...
ncsacw.samhsa.govinfants and their families affected by prenatal substance exposure • Supported two regional convenings—along with the Department of Health and Human Services regions 4, 6, 7, and 9, and their respective state teams—to advance their capacity to improve the safety, permanency, recovery, and well-being of infants and their families
TOXICOLOGICAL PROFILE FOR PROPYLENE GLYCOL
www.atsdr.cdc.govPROPYLENE GLYCOL iii UPDATE STATEMENT A Technical Report for propylene glycol was released in May 1993. This edition supersedes any previously released draft …
Toxicological Profile for Perfluoroalkyls
www.atsdr.cdc.govPERFLUOROALKYLS ii . DISCLAIMER . Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human
M 4 E Common Technical Document for the Registration of ...
www.ema.europa.eu2.5.1. Product Development Rationale 2.5.2. Overview of Biopharmaceutics 2.5.3. Overview of Clinical Pharmacology 2.5.4. Overview of Efficacy 2.5.5. Overview of Safety 2.5.6. Benefits and Risks Conclusions 2.5.7. Literature References Detailed Discussion of Content of the Clinical Overview Sections 2.5.1 Product Development Rationale
M4E(R2) - Common technical document for the registration ...
www.ema.europa.eu2.5.4 Overview of Efficacy 2.5.5 Overview of Safety 2.5.6 Benefits and Risks Conclusions 2.5.6.1 Therapeutic Context 2.5.6.1.1 Disease or Condition 2.5.6.1.2 Current Therapies 2.5.6.2 Benefits 2.5.6.3 Risks 2.5.6.4 Benefit-Risk Assessment 2.5.6.5 Appendix 2.5.7 Literature References Detailed discussion of content of the clinical overview ...